We have our new newsletter is available!! New news and articles letting you know the latest news in regards to CLL and the Blood Cancer Research Fund. Special thanks to Carolina Bump for her tireless efforts to get this information together!
Have you seen the new Jacob’s Medical Center building being built just across from the Moores Cancer Center? To read more about the project and the incredible commitment to creating a healthier world, CLICK HERE!
The $839 million facility is part of a multi-billion dollar university investment in the future of health care for the entire region. It will allow UC San Diego Health System to fulfill its potential of becoming one of the country’s premier academic health systems.
B-cell chronic lymphocytic leukemia (CLL) is the most common adult leukemia in Western societies.1 CLL cases can be subgrouped into two types, aggressive or indolent, defined as cases that express high levels of Zeta-chain-associated protein kinase 70 (ZAP70) and unmutated immunoglobulin heavy-chain variable-region genes (IGHV), or low to negligible ZAP70 and mutated IGHV. Chromosomal aberrations can be identified in more than 80% of patients.1 The most frequent genetic alterations include deletion/inactivation of 13q14 (>50%), deletion of 11q22–23 (18%), trisomy of 12 (12–16%) and deletion 17p (7–10%).1
Trisomy 12 identified using Fluorescent In Situ Hybridization (FISH)